UB Molecular Recognition in Biological Systems and Bioinformatics News
UB's BioBlower Closer to Protecting Soldiers from Biological Attack
A powerful air sterilization technology developed at the University at Buffalo has killed every biological agent with which it has been challenged, including airborne spores, viruses and bacteria in independent tests conducted for the U.S. Department of Defense. 
Novel Molecules Developed at UB Can Boost Vaccine Potency
Two novel proteins studied by a University at Buffalo professor of microbiology and immunology appear to have the potential to enhance the production of antibodies against a multitude of infectious agents.
New Method Enables Design, Production of Extremely Novel Drugs
A new chemical synthesis method based on a catalyst worth many times the price of gold and providing a far more efficient and economical method than traditional ones for designing and manufacturing extremely novel pharmaceutical compounds is described by its University at Buffalo developers in a review article in the current issue of Nature.
Million Dollar Gift Will Help Construct New UB Engineering Building
A $1 million gift to the University at Buffalo School of Engineering and Applied Sciences from a global industry leader with a strong interest in Western New York will be used for costs associated with the construction of a new, high-tech engineering building on UB's North (Amherst) Campus.
Study to Identify Risk Factors for Staph Bloodstream Complications
In an effort to improve this process and develop new guidelines for antibiotic use for a potentially deadly staph infection, University at Buffalo researchers are collecting bacterial isolates and clinical information from SAB-infected patients hospitalized in three area hospitals and following their charted progress through inpatient treatment, discharge and for a post-discharge period.
Study on Toxin that Tainted Spinach Reveals Treatment Possibility
A discovery by University at Buffalo biologists that may explain the evolution of a lethal toxin is providing new information that could lead to more effective treatments for humans who fall victim to it.
Buffalo-Made Anti-Cancer Drug Begins Human Trials
An anti-cancer drug developed by Kinex Pharmaceuticals of Buffalo and a University at Buffalo faculty researcher has begun clinical testing with patients.
Oishei Grant Will Improve UB Diagnostic Tools in Psychiatry
A $148,328 grant from the John R. Oishei Foundation will establish a multidisciplinary task force for ontology-based IT support for large-scale field studies in psychiatry at the University at Buffalo.
NIH Funds UB Search for New Drug for Neurodegenerative Disease
A professor of biochemistry in the School of Medicine and Biomedical Sciences at the University at Buffalo, has received a two-year, $418,363 grant from the National Institutes of Health to develop a drug aimed at an iron-based neurodegenerative disease called aceruloplasminemia.
Straubinger Named to NIH Study Section
The National Institutes of Health Center for Scientific Review has appointed Robert M. Straubinger, professor in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences, to serve as a member of its Drug Discovery and Molecular Pharmacology Study Section.
